BOULDER, Colo.–(BUSINESS WIRE)—- $BDSX #patientsfirst–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it has commenced an underwritten public offering of $30 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. In connection with the offering, Biodesix intends to grant the underwriters a 30-day option to purchase up to an additional $4.5 million of shares of its
Click here to view original post
News
Terran Orbital Showcases Key Programs at 2024 Space Symposium
COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Today, Terran Orbital Corporation (NYSE: LLAP) (“Terran Orbital” or the “Company”), a global leader in satellite-based solutions primarily serving the aerospace and defense industries, announces its space-related technologies and programs for the […]
News
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
FOSTER CITY, Calif.–(BUSINESS WIRE)– #CROI2026–Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the […]
News
Sandoz to pay Allergan, Duke University $39M over eye drug lawsuit, jury says
Sandoz is on the hook for $39 million to Allergan and Duke University for infringing on their patent for an eyelash-growth drug, Latisse (bimatoprost ophthalmic solution), a Colorado federal jury decided Friday. In a complaint […]
